We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-6.12%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.71B
AUM Growth
-$811M
Cap. Flow
-$127M
Cap. Flow %
-2.7%
Top 10 Hldgs %
32.95%
Holding
146
New
21
Increased
16
Reduced
26
Closed
19

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$114M
2
APLM icon
Apollomics
APLM
+$84.7M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$55.1M
4
ABBV icon
AbbVie
ABBV
+$48.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$37.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.2M
2
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$87.7M
3
UNH icon
UnitedHealth
UNH
+$85.6M
4
EW icon
Edwards Lifesciences
EW
+$48.6M
5
BAX icon
Baxter International
BAX
+$48.4M

Sector Composition

Rank Sector Weight
1 Healthcare 96.83%
2 Miscellaneous 1.94%
3 Industrials 1.1%
4 Consumer Staples 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
101
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.36M 0.09%
+100,000
New +$3.57M
RLAY icon
102
Relay Therapeutics
RLAY
$4.18B
$4.22M 0.09%
+501,966
New +$5.4M
LSB
103
DELISTED
LakeShore Biopharma
LSB
$3.63M 0.08%
454,142
+24,295
+6% +$280K
CUTR
104
DELISTED
Cutera, Inc.
CUTR
$3.63M 0.08%
603,100
+216,000
+56% +$2.74M
NXTC icon
105
NextCure
NXTC
$30.4M
$3.5M 0.07%
225,918
– –
APLS
106
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$2.95M 0.06%
+77,500
New +$3.4M
EPIX
107
DELISTED
ESSA Pharma
EPIX
$2.6M 0.06%
842,366
-79,574
-9% -$229K
VIGL
108
DELISTED
Vigil Neuroscience
VIGL
$2.42M 0.05%
448,891
– –
KRTX
109
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$2.37M 0.05%
+14,000
New +$2.63M
TDOC icon
110
Teladoc Health
TDOC
$1.18B
$2.04M 0.04%
+110,000
New +$2.57M
CMMB
111
Chemomab Therapeutics
CMMB
$18M
$2.01M 0.04%
560,319
– –
AFIB
112
DELISTED
Acutus Medical Inc
AFIB
$1.84M 0.04%
2,648,386
– –
BCAB
113
DELISTED
BIOATLA INC
BCAB
$1.72M 0.04%
20,186
-2,938
-13% -$374K
HLSQ
114
Tessera Defense and Homeland Security Inc.
HLSQ
$2.89M
$1.6M 0.03%
2,397
– –
BOLT icon
115
Bolt Biotherapeutics
BOLT
$7.61M
$1.6M 0.03%
77,050
– –
IMTX icon
116
CALL
Immatics
IMTX
$1.34B
$1.45M 0.03%
+125,000
New +$1.49M
TARA icon
117
Protara Therapeutics
TARA
$231M
$1.29M 0.03%
772,584
– –
SYBX
118
DELISTED
Synlogic
SYBX
$1.13M 0.02%
401,998
-2
-0% -$14
ELEV
119
DELISTED
Elevation Oncology
ELEV
$994K 0.02%
1,500,000
– –
HRTX icon
120
Heron Therapeutics
HRTX
$59.9M
$827K 0.02%
802,700
– –
CALC icon
121
CalciMedica
CALC
$13.7M
$791K 0.02%
59,476
– –
DMRA
122
Damora Therapeutics
DMRA
$1.73B
$665K 0.01%
36,992
-116,377
-76% -$4.57M
XNCR icon
123
Xencor
XNCR
$1.82B
$386K 0.01%
+19,142
New +$435K
ALT icon
124
Altimmune
ALT
$642M
$260K 0.01%
100,000
– –
HARP
125
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$250K 0.01%
62,121
-1
-0% -$7
2 3 4
5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2023 Portfolio in Review

As of Q3 2023, OrbiMed held 146 positions worth $4.71B, down 15% from $5.52B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed's Q3 2023 filing shows 21 new, 16 increased, 26 reduced and 19 closed positions. Its largest new stake was Merck: 1,055,000 shares worth $109M. The largest sale was Bristol-Myers Squibb, an estimated $95.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Industrials.

  • OrbiMed's largest Q3 2023 buy was Merck: 1,055,000 shares worth $109M.
  • OrbiMed added most to Apollomics in Q3 2023, an estimated $84.7M increase.
  • OrbiMed's biggest Q3 2023 reduction was UnitedHealth, cutting an estimated $85.6M.
  • OrbiMed fully exited Bristol-Myers Squibb in Q3 2023, selling an estimated $95.2M.
  • OrbiMed's ten largest holdings make up 33% of its $4.71B portfolio in Q3 2023.
  • OrbiMed opened 21 new positions and closed 19 in Q3 2023.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $4.71B.

Based on OrbiMed's 13F filing for Q3 2023, filed 14 Nov 2023.